The cerebral vasculopathy of Fabry disease

被引:105
作者
Moore, David F.
Kaneski, Christine R.
Askari, Hasan
Schiffmann, Raphael
机构
[1] NINDS, NIH, Dev & Metab Neurol Branch, Bethesda, MD 20892 USA
[2] Univ Manitoba, Neurol Sect, Winnipeg, MB R3C 4J5, Canada
关键词
stroke; atherosclerosis; Fabry disease; lysosomal disease; x-linked disorder; glycolipid; vasculopathy;
D O I
10.1016/j.jns.2007.01.053
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Fabry disease is an X-linked disorder affecting both males and females. It is associated with an increased risk of stroke in up to 4% of patients below 55 years of age in the general population. The cerebral vasculopathy consists of ischemic strokes involving large and small vessels. The neuronal accumulation of glycosphingolipids appears to have no clinical effect on the natural history of Fabry disease with the possible exception of some reported mild cognitive abnormalities. The pathogenesis of Fabry vasculopathy remains poorly understood but is associated with abnormal functional control of the vessel secondary to endothelial dysfunction, cerebral hyper-perfusion and a prothrombotic state with likely increased production of reactive oxygen species. These abnormalities are further modified by genetic and possibly other vascular risk factors. This vasculopathy illustrates the role of glycolipids in this and possibly other types of cerebral vasculopathies. Therapy is preventive relying on standard medical care and in particular on anti-platelet agents such as clopidogrel. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:258 / 263
页数:6
相关论文
共 38 条
  • [1] Enhanced endothelium-dependent vasodilation in Fabry disease
    Altarescu, G
    Moore, DF
    Pursley, R
    Campia, U
    Goldstein, S
    Bryant, M
    Panza, JA
    Schiffmann, R
    [J]. STROKE, 2001, 32 (07) : 1559 - 1562
  • [2] Effect of genetic modifiers on cerebral lesions in Fabry disease
    Altarescu, G
    Moore, DF
    Schiffmann, R
    [J]. NEUROLOGY, 2005, 64 (12) : 2148 - 2150
  • [3] ANDERSON WA, 1898, BRIT J DERMATOL, V18, P113
  • [4] ANGIOKERATOMA CORPORIS DIFFUSUM UNIVERSALE (FABRYS DISEASE) IN 2 BROTHERS
    BETHUNE, JE
    LANDRIGAN, PL
    CHIPMAN, CD
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1961, 264 (25) : 1280 - &
  • [5] α-Galactosidase A deficiency accelerates atherosclerosis in mice with apolipoprotein E deficiency
    Bodary, PF
    Shen, YS
    Vargas, FB
    Bi, XM
    Ostenso, KA
    Gu, SF
    Shayman, JA
    Eitzman, DT
    [J]. CIRCULATION, 2005, 111 (05) : 629 - 632
  • [6] BROWN A, 1952, Glasgow Med J, V33, P361
  • [7] Quantitative analysis of cerebral vasculopathy in patients with Fabry disease
    Crutchfield, KE
    Patronas, NJ
    Dambrosia, JM
    Frei, KP
    Banerjee, TK
    Barton, NW
    Schiffmann, R
    [J]. NEUROLOGY, 1998, 50 (06) : 1746 - 1749
  • [8] DeGraba T, 2000, ANN NEUROL, V47, P229, DOI 10.1002/1531-8249(200002)47:2<229::AID-ANA13>3.0.CO
  • [9] 2-T
  • [10] Safety and efficacy of recombinant human α-galactosidase a replacement therapy in Fabry's disease.
    Eng, CM
    Guffon, N
    Wilcox, WR
    Germain, DP
    Lee, P
    Waldek, S
    Caplan, L
    Linthorst, GE
    Desnick, RJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (01) : 9 - 16